PALO ALTO, CA — December 5, 2025 — Guardant Health announced it will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting major advancements in its multiomic liquid biopsy technologies used to predict outcomes, monitor treatment response, and guide therapeutic decisions in early and metastatic breast cancer. The presentations feature findings generated using Guardant Reveal, the company’s minimal residual disease (MRD) test, and Guardant360 Liquid, a comprehensive multiomic profiling assay powered by the Guardant Infinity Smart Platform.
Science Significance
The new data advance the scientific understanding of how tissue-free, multiomic liquid biopsy approaches can detect cancer recurrence, evaluate risk, and track tumor evolution in real time. Results across the 14 abstracts demonstrate that circulating tumor DNA (ctDNA) and methylation-based signatures provide highly sensitive, biologically relevant markers for treatment response and disease progression. Studies of HER2-positive and triple-negative cohorts show that ctDNA levels correlate with pathological complete response, relapse risk, and invasive disease-free survival, reaffirming liquid biopsy’s role in uncovering dynamic tumor biology with unprecedented precision.
Regulatory Significance
The breadth of clinical evidence debuting at SABCS strengthens the regulatory foundation for future indications and validation pathways for Guardant’s liquid biopsy tests. Multiomic assays like Guardant Reveal and Guardant360 Liquid must meet rigorous analytical validity, clinical validity, and clinical utility standards under global diagnostic regulatory frameworks. The data presented—spanning MRD detection, subtype monitoring, real-world genomic analyses, and treatment-response correlations—help position these tools for expanded regulatory consideration, including potential use as companion diagnostics, post-treatment surveillance methods, and therapeutic decision-support tools. The studies also reinforce GxP-aligned expectations around test reproducibility, assay robustness, and clinical reliability.
Business Significance
Advertisement
For Guardant Health, the presentations mark a significant reinforcement of its competitive leadership in the rapidly expanding precision oncology diagnostics market. The company’s multiomic platform is demonstrating strong applicability across early-stage disease management, metastatic monitoring, and therapeutic guidance—areas representing high commercial demand and substantial global growth potential. Showcasing high-impact data at a flagship oncology meeting strengthens Guardant’s position with biopharma collaborators, supports payer engagement for test reimbursement, and expands opportunities for clinical trial integration. These results also enhance the company’s differentiation amid increasing activity in the liquid biopsy field.
Patients’ Significance
For breast cancer patients, the findings underscore the power of non-invasive, accurate, and actionable liquid biopsy testing. Early and metastatic patients frequently face the burden of repeated tissue biopsies, delayed detection, and uncertainty around treatment efficacy. Guardant Reveal’s ability to detect MRD earlier and more sensitively than traditional methods—and Guardant360 Liquid’s capacity to track methylation-based subtype shifts—provide essential insights that can improve treatment alignment and long-term outcomes. These diagnostics enable clinicians to anticipate relapse, escalate or de-escalate therapy, and personalize care with greater clarity and confidence, ultimately shaping a more patient-centered oncology experience.
Policy Significance
The expansion of clinical evidence supporting multiomic liquid biopsy aligns with global policy priorities emphasizing precision medicine, early detection, equitable access to molecular diagnostics, and improved cancer-care efficiency. Public-health authorities increasingly recognize liquid biopsy as a key component of modern oncology infrastructure, particularly where tissue access is limited or repeated biopsies are impractical. The findings presented at SABCS support ongoing policy discussions around diagnostic reimbursement, integration into screening and monitoring pathways, and regulatory frameworks for ctDNA-based technologies, helping pave the way for broader adoption in clinical practice and national cancer strategies.
With 14 abstracts unveiling new insights across MRD detection, therapeutic response monitoring, and multiomic subtype evaluation, Guardant Health demonstrates compelling scientific and clinical leadership at SABCS 2025. The company’s expanding body of evidence reinforces the transformative role of liquid biopsy in guiding breast cancer care from early disease through metastatic progression. As precision oncology continues to evolve, Guardant’s innovations stand at the forefront of delivering real-time molecular clarity, powering more informed decisions for clinicians and better outcomes for patients worldwide.
Source: Guardant Health, Inc. press release
